Crohn's & colitis 360
Cure8 research brief
Why This Matters
Faster remission can reduce symptoms, school disruption, and steroid exposure for children with IBD. If earlier infliximab level checks reliably speed remission, clinicians could adjust dosing sooner to improve outcomes.
Who Should Pay Attention
Pediatric IBD patients and their caregivers, pediatric gastroenterologists, clinicians managing children on infliximab, and researchers studying therapeutic drug monitoring in biologic therapy.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This retrospective cohort from a single pediatric center compared children who had induction‑phase therapeutic drug monitoring (I‑TDM) to those who had monitoring later in maintenance (M‑TDM). After matching, the I‑TDM group reached clinical remission sooner (median 140 vs. 203 days) and I‑TDM remained associated with faster remission in adjusted analyses.
The authors suggest that earlier TDM allows prompt dose adjustments before the third infusion. The study used real-world electronic records and propensity score matching but is observational and from one center, so it cannot prove causation.
It reports time-to-remission outcomes and timing to achieve target IFX levels, with no clear differences in long-term complications between groups.
Practical takeaways: Induction‑phase TDM of infliximab is a strategy clinicians may consider to shorten time to remission in pediatric IBD, but findings should be confirmed in prospective or multicenter studies before broad practice change.
Keep In Mind
This is a retrospective, single‑center cohort using propensity score matching; observational design cannot establish causality. The article is provided as an abstract-level structured source, not a full multicenter randomized trial. Local practice, lab availability, and cost considerations affect whether early TDM is feasible.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCrohn's & colitis 360
AuthorsIovino N, Paglinco SR, Abdel-Rasoul M +4 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 20, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing.
Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...
Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Disease
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...